L'approche experimentale de la chimiotherapie de la tuberculose

Translated title of the contribution: Experimental approach of chemotherapy for tuberculosis

J. Grosset

Research output: Contribution to journalArticle

Abstract

Because it is easy to handle in terms of size, supply, maintenance, robustness and reproducibility, the mouse infected with Mycobacterium tuberculosis and treated with antimicrobial drugs is the choice model for experimental chemotherapy on tuberculosis. It provides results that may be applied to man on the condition that age, race, body weight of mice are precisely defined as well as the strain of M. tuberculosis used (at best the H37Rv reference strain), the way its virulence is maintained and subcultures are made. In addition, because of the important pharmacokinetic differences between mice and man, antimicrobial drugs should be given to the mouse only at dosages equivalent to those given to man, at best in terms of AUC. Experimental methods to test the activity of a single drug are different from the methods used to test the activity of a drug combination. In the first case to prevent a possible interference with the selection of drug resistant mutants, either mice are infected with 5 x 103 cfu and the treatment starts two weeks later when the microbial population reaches 106 cfu or they infected with 106 cfu and the treatment starts on the day after infection. In the second case, mice are infected with 5 x 106 cfu and the treatment starts two weeks later when the microbial population reaches 108 cfu. Experimental chemotherapy for tuberculosis could lead to: possible improvements of the present short-course chemotherapy by further shortening the total duration of treatment or by increasing the intervals between drug administration; new regimens for the treatment of multidrug resistant tuberculosis; and curative and preventive treatment of tuberculosis in HIV-infected patients.

Original languageFrench
Pages (from-to)922-925
Number of pages4
JournalMedecine et Maladies Infectieuses
Volume26
Issue number11
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Tuberculosis
Drug Therapy
Pharmaceutical Preparations
Mycobacterium tuberculosis
Therapeutics
Multidrug-Resistant Tuberculosis
Drug Combinations
Population
Area Under Curve
Virulence
Theoretical Models
Pharmacokinetics
Body Weight
Maintenance
HIV
Infection

Keywords

  • experimental chemotherapy
  • murine model
  • tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

L'approche experimentale de la chimiotherapie de la tuberculose. / Grosset, J.

In: Medecine et Maladies Infectieuses, Vol. 26, No. 11, 1996, p. 922-925.

Research output: Contribution to journalArticle

@article{699e80a7337248098bcda863db46af9c,
title = "L'approche experimentale de la chimiotherapie de la tuberculose",
abstract = "Because it is easy to handle in terms of size, supply, maintenance, robustness and reproducibility, the mouse infected with Mycobacterium tuberculosis and treated with antimicrobial drugs is the choice model for experimental chemotherapy on tuberculosis. It provides results that may be applied to man on the condition that age, race, body weight of mice are precisely defined as well as the strain of M. tuberculosis used (at best the H37Rv reference strain), the way its virulence is maintained and subcultures are made. In addition, because of the important pharmacokinetic differences between mice and man, antimicrobial drugs should be given to the mouse only at dosages equivalent to those given to man, at best in terms of AUC. Experimental methods to test the activity of a single drug are different from the methods used to test the activity of a drug combination. In the first case to prevent a possible interference with the selection of drug resistant mutants, either mice are infected with 5 x 103 cfu and the treatment starts two weeks later when the microbial population reaches 106 cfu or they infected with 106 cfu and the treatment starts on the day after infection. In the second case, mice are infected with 5 x 106 cfu and the treatment starts two weeks later when the microbial population reaches 108 cfu. Experimental chemotherapy for tuberculosis could lead to: possible improvements of the present short-course chemotherapy by further shortening the total duration of treatment or by increasing the intervals between drug administration; new regimens for the treatment of multidrug resistant tuberculosis; and curative and preventive treatment of tuberculosis in HIV-infected patients.",
keywords = "experimental chemotherapy, murine model, tuberculosis",
author = "J. Grosset",
year = "1996",
doi = "10.1016/S0399-077X(96)80198-3",
language = "French",
volume = "26",
pages = "922--925",
journal = "Medecine et Maladies Infectieuses",
issn = "0399-077X",
publisher = "Elsevier Masson",
number = "11",

}

TY - JOUR

T1 - L'approche experimentale de la chimiotherapie de la tuberculose

AU - Grosset, J.

PY - 1996

Y1 - 1996

N2 - Because it is easy to handle in terms of size, supply, maintenance, robustness and reproducibility, the mouse infected with Mycobacterium tuberculosis and treated with antimicrobial drugs is the choice model for experimental chemotherapy on tuberculosis. It provides results that may be applied to man on the condition that age, race, body weight of mice are precisely defined as well as the strain of M. tuberculosis used (at best the H37Rv reference strain), the way its virulence is maintained and subcultures are made. In addition, because of the important pharmacokinetic differences between mice and man, antimicrobial drugs should be given to the mouse only at dosages equivalent to those given to man, at best in terms of AUC. Experimental methods to test the activity of a single drug are different from the methods used to test the activity of a drug combination. In the first case to prevent a possible interference with the selection of drug resistant mutants, either mice are infected with 5 x 103 cfu and the treatment starts two weeks later when the microbial population reaches 106 cfu or they infected with 106 cfu and the treatment starts on the day after infection. In the second case, mice are infected with 5 x 106 cfu and the treatment starts two weeks later when the microbial population reaches 108 cfu. Experimental chemotherapy for tuberculosis could lead to: possible improvements of the present short-course chemotherapy by further shortening the total duration of treatment or by increasing the intervals between drug administration; new regimens for the treatment of multidrug resistant tuberculosis; and curative and preventive treatment of tuberculosis in HIV-infected patients.

AB - Because it is easy to handle in terms of size, supply, maintenance, robustness and reproducibility, the mouse infected with Mycobacterium tuberculosis and treated with antimicrobial drugs is the choice model for experimental chemotherapy on tuberculosis. It provides results that may be applied to man on the condition that age, race, body weight of mice are precisely defined as well as the strain of M. tuberculosis used (at best the H37Rv reference strain), the way its virulence is maintained and subcultures are made. In addition, because of the important pharmacokinetic differences between mice and man, antimicrobial drugs should be given to the mouse only at dosages equivalent to those given to man, at best in terms of AUC. Experimental methods to test the activity of a single drug are different from the methods used to test the activity of a drug combination. In the first case to prevent a possible interference with the selection of drug resistant mutants, either mice are infected with 5 x 103 cfu and the treatment starts two weeks later when the microbial population reaches 106 cfu or they infected with 106 cfu and the treatment starts on the day after infection. In the second case, mice are infected with 5 x 106 cfu and the treatment starts two weeks later when the microbial population reaches 108 cfu. Experimental chemotherapy for tuberculosis could lead to: possible improvements of the present short-course chemotherapy by further shortening the total duration of treatment or by increasing the intervals between drug administration; new regimens for the treatment of multidrug resistant tuberculosis; and curative and preventive treatment of tuberculosis in HIV-infected patients.

KW - experimental chemotherapy

KW - murine model

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0030445781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030445781&partnerID=8YFLogxK

U2 - 10.1016/S0399-077X(96)80198-3

DO - 10.1016/S0399-077X(96)80198-3

M3 - Article

VL - 26

SP - 922

EP - 925

JO - Medecine et Maladies Infectieuses

JF - Medecine et Maladies Infectieuses

SN - 0399-077X

IS - 11

ER -